Identification of inherited cancer-predisposing genes offers opportunities for cancer prevention. Inherited susceptibility genes have been identified, primarily through studies of unusual cancer cases and families but also through general population studies. Examples include the RB1 gene for retinoblastoma; the INT1 gene for Wilms' tumor; germline p53 mutations in families with the Li-Fraumeni syndrome; the NF1 and NF2 genes for neuroblastomatosis, types 1 and 2; the VHL gene for renal cancer and other tumors associated with Von Hippel-Lindau disease; the APC gene for adenomatous polyposis coli; the BRCA1 gene for hereditary breast and ovarian cancer; and the mismatch repair genes for colon and other common cancers. For some cancers, identification of gene carriers might be beneficial for targeting screening and chemopreventive interventions. On the other hand, predisposition testing for cancer has the potential for harm from loss of insurability and employability, psychological distress, social stigmatization and other adverse effects. Research is needed to identify predisposition testing procedures that maximize benefits while minimizing harm to subjects. Chemoprevention trials in genetically susceptible populations offer the prospect of finding effective methods of reducing future cancer risk. -Environ Health Perspect 1 03(Suppl 8): 297-300 (1995) 
Introduction
Speakers at this meeting have summarized current knowledge of cancer etiology and considered opportunities for prevention. Epidemiological studies of human populations have demonstrated the carcinogenic effects of ionizing and ultraviolet radiation, tobacco, alcoholic beverages, viral and bacterial agents, and chemical compounds (1, 2) . In the 1994 Annual Report on Carcinogens (3), nearly two dozen substances, occupational exposures, and medical treatments were classified as carcinogenic in humans. Many more substances were said to be "reasonably anticipated to be carcinogens," but uncertainties remain. Presently, known carcinogens account for perhaps half the incident cancers in the United States. For many common forms of cancer, such as cancers of the breast, prostate, and gastrointestinal tract, lifestyle factors have been implicated, although specific causes have been difficult to pinpoint.
A constant challenge to cancer epidemiologists is the relatively small excess risk associated with exposures to many suspected carcinogens (4) . To overcome the problem, researchers are utilizing laboratory tools to refine dose-response relationships and to reinforce the biological plausibility of hypotheses (5) . Molecular biomarkers also can be applied to classify patients and strengthen associations in study subgroups (6) . In this emerging era of molecular epidemiology, substantial progress has been made in the identification of inherited single-gene traits that markedly increase cancer risk (7) . In the future, the knowledge of the more complex genetic systems involved in the activation and detoxification of carcinogens should further enhance the power of cancer epidemiology, as described in Rothman's paper (8) . This overview will explore opportunities for cancer prevention based on recent discoveries of inherited cancer-predisposing genes.
Cancer Fanilies and Cancer
Susceptibility Genes
Historically, the effects of inherited cancer susceptibility genes were discerned through studies of cancer occurrence in families. More recent advances in cytogenetics provided the first glimpses of inherited genetic changes that confer susceptibility to cancer. In 1986, the first inherited cancer susceptibility gene, the RB1 gene for retinoblastoma, was cloned (9) . Since then, a dozen such genes have been identified, mostly through studies of unusual cases and families.
Epidemiological studies have consistently shown that a family history of cancer is a risk factor for virtually all forms of neoplasia in humans (10) . The relative risk is typically 1.5-to 3-fold for the forms of cancer that have occurred in close relatives. In some instances, the elevated risk extends to multiple organ sites, as in the multiple endocrine neoplasia syndromes (11 (11, 12) . In these studies, and PMSI and PMS2) for colon and other clinicians and epidemiologists provided common cancers (16) (17) (18) A common misconception is that a positive genetic test predicts that cancer will develop, whereas a negative test is associated with the baseline population frequency for that cancer (23 Identification of an inherited susceptibility gene per se provides no benefit to the subject. Benefit from cancer predisposition testing accrues when primary prevention, targeted screening, and more effective treatments lead to reduced morbidity and mortality (24) . Finding carriers of inherited susceptibility genes creates an obligation to develop strategies for the care of these cancer-prone individuals. Increased medical surveillance might detect early cancers in at-risk organs and tissues. For example, identification of an inherited RBJ mutation in an at-risk infant can lead to surveillance and curative treatments with minimal loss of eyesight. Benefits of targeted screening might also accrue to carriers of colon and breast cancer susceptibility genes (25) . Targeted colonoscopies can lead to excision of pre-cancerous polyps, but the procedure is neither inexpensive nor free of morbidity. An alternative is primary prevention through reducing exposures to carcinogens among those with inherited susceptibility to cancer. Avoidance of sunlight exposure in patients with xeroderma pigmentosum or hereditary melanoma can reduce the risk of skin neoplasms. Dietary modification might reduce the risk of colon and other cancers in gene carriers, but sustained change in dietary practices is difficult to achieve. There are a few indications at present to perform prophylactic surgery to remove the target organs in genetically susceptible individuals. Prophylactic total colectomy is standard treatment for patients with adenomatous polyposis coli due to the APC gene. However, morbidity of the procedure is high, and deaths from dismoid tumors arising at the surgical site are frequent. A few patients in breast-ovarian cancer families have undergone prophylactic mastectomy, oophorectomy, or both. Unfortunately, abdominal carcinomatosis have developed subsequent to prophylactic oophorectomy in rare cases, and the extent of risk reduction after prophylactic mastectomy is not known A new and exciting area of research is chemoprevention (26) . The goal of chemoprevention is to prevent or delay cancer occurrence through the use of chemical agents. Chemopreventive agents under study include natural and synthetic products including vitamin micronutrients, natural compounds, and pharmaceutical agents. A growing number of clinical chemoprevention trials are in progress, and early results from several studies have been encouraging. Target populations in these studies include cancer patients at high risk of second cancers, those with precancerous lesions, and carriers of cancer susceptibility genes. The latter are an attractive group for chemoprevention trials, in part because their risk of future cancer development is exceptionally high. In these groups, chemopreventive agents with some toxicity might be acceptable. Chemoprevention trials require large numbers of subjects. When cancer prevention is the end point, studies should be extended over many years; their cost is high. Intermediate biomarkers of efficacy could give early indications of benefit. Unfortunately, validated biomarkers have been difficult to identify and their predictive power is difficult to measure. Problems notwithstanding, chemoprevention trials in genetically susceptible populations offer the prospect of finding effective methods of reducing future cancer risk.
